This week started off with a bang for the healthcare industry as two VC-backed biotechs completed exits. Bioinformatics company Spiral Genetics was purchased by Omicia and Gen9, which specializes in the synthesis and assembly of DNA constructs, was acquired by Ginkgo Bioworks (more on those deals in our "Exits" section below).
Since the beginning of 2014, 495 venture investors have participated in at least one of the 456 deals backing a US-based biotech startup, according to the PitchBook Platform. Investment activity saw a sharp rise from 2014 to 2015, with capital invested and deal count increasing 107% and 43%, respectively. 2016 levels were similar to those of 2015, logging $3.5 billion disbursed through 169 financings. California-based startups accounted for 36% of US deals since 2014, followed by Massachusetts (22.6%) and New York (4.6%).
Here are the top 11 VCs investing in the biotech industry, along with their investment counts (not including accelerator rounds):